NEW YORK (GenomeWeb News) – Start-up molecular diagnostics firm NexDx said today it has completed its Series B financing round, bringing in $2.1 million.

The round was led by founding investor City Hill Ventures. Silicon Valley Bank also is providing a $500,000 capital term loan to the San Diego-based company. The funding will be used to support continued R&D and further NexDx's lead diagnostic test for rheumatoid arthritis into analytical and clinical validation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.